A landscape of genomic alterations at the root of a near-untreatable tuberculosis epidemic.
Atypical Beijing
Bedaquiline
Beyond-XDR-TB
Drug-resistant
Missed resistance
Tuberculosis
Weakened regimen
Whole genome sequencing
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
04 02 2020
04 02 2020
Historique:
received:
19
08
2019
accepted:
24
12
2019
entrez:
5
2
2020
pubmed:
6
2
2020
medline:
2
10
2020
Statut:
epublish
Résumé
Atypical Beijing genotype Mycobacterium tuberculosis strains are widespread in South Africa and have acquired resistance to up to 13 drugs on multiple occasions. It is puzzling that these strains have retained fitness and transmissibility despite the potential fitness cost associated with drug resistance mutations. We conducted Illumina sequencing of 211 Beijing genotype M. tuberculosis isolates to facilitate the detection of genomic features that may promote acquisition of drug resistance and restore fitness in highly resistant atypical Beijing forms. Phylogenetic and comparative genomic analysis was done to determine changes that are unique to the resistant strains that also transmit well. Minimum inhibitory concentration (MIC) determination for streptomycin and bedaquiline was done for a limited number of isolates to demonstrate a difference in MIC between isolates with and without certain variants. Phylogenetic analysis confirmed that two clades of atypical Beijing strains have independently developed resistance to virtually all the potent drugs included in standard (pre-bedaquiline) drug-resistant TB treatment regimens. We show that undetected drug resistance in a progenitor strain was likely instrumental in this resistance acquisition. In this cohort, ethionamide (ethA A381P) resistance would be missed in first-line drug-susceptible isolates, and streptomycin (gidB L79S) resistance may be missed due to an MIC close to the critical concentration. Subsequent inadequate treatment historically led to amplification of resistance and facilitated spread of the strains. Bedaquiline resistance was found in a small number of isolates, despite lack of exposure to the drug. The highly resistant clades also carry inhA promoter mutations, which arose after ethA and katG mutations. In these isolates, inhA promoter mutations do not alter drug resistance, suggesting a possible alternative role. The presence of the ethA mutation in otherwise susceptible isolates from ethionamide-naïve patients demonstrates that known exposure is not an adequate indicator of drug susceptibility. Similarly, it is demonstrated that bedaquiline resistance can occur without exposure to the drug. Inappropriate treatment regimens, due to missed resistance, leads to amplification of resistance, and transmission. We put these results into the context of current WHO treatment regimens, underscoring the risks of treatment without knowledge of the full drug resistance profile.
Sections du résumé
BACKGROUND
Atypical Beijing genotype Mycobacterium tuberculosis strains are widespread in South Africa and have acquired resistance to up to 13 drugs on multiple occasions. It is puzzling that these strains have retained fitness and transmissibility despite the potential fitness cost associated with drug resistance mutations.
METHODS
We conducted Illumina sequencing of 211 Beijing genotype M. tuberculosis isolates to facilitate the detection of genomic features that may promote acquisition of drug resistance and restore fitness in highly resistant atypical Beijing forms. Phylogenetic and comparative genomic analysis was done to determine changes that are unique to the resistant strains that also transmit well. Minimum inhibitory concentration (MIC) determination for streptomycin and bedaquiline was done for a limited number of isolates to demonstrate a difference in MIC between isolates with and without certain variants.
RESULTS
Phylogenetic analysis confirmed that two clades of atypical Beijing strains have independently developed resistance to virtually all the potent drugs included in standard (pre-bedaquiline) drug-resistant TB treatment regimens. We show that undetected drug resistance in a progenitor strain was likely instrumental in this resistance acquisition. In this cohort, ethionamide (ethA A381P) resistance would be missed in first-line drug-susceptible isolates, and streptomycin (gidB L79S) resistance may be missed due to an MIC close to the critical concentration. Subsequent inadequate treatment historically led to amplification of resistance and facilitated spread of the strains. Bedaquiline resistance was found in a small number of isolates, despite lack of exposure to the drug. The highly resistant clades also carry inhA promoter mutations, which arose after ethA and katG mutations. In these isolates, inhA promoter mutations do not alter drug resistance, suggesting a possible alternative role.
CONCLUSION
The presence of the ethA mutation in otherwise susceptible isolates from ethionamide-naïve patients demonstrates that known exposure is not an adequate indicator of drug susceptibility. Similarly, it is demonstrated that bedaquiline resistance can occur without exposure to the drug. Inappropriate treatment regimens, due to missed resistance, leads to amplification of resistance, and transmission. We put these results into the context of current WHO treatment regimens, underscoring the risks of treatment without knowledge of the full drug resistance profile.
Identifiants
pubmed: 32014024
doi: 10.1186/s12916-019-1487-2
pii: 10.1186/s12916-019-1487-2
pmc: PMC6998097
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
24Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : EXC 22167-390884018
Pays : International
Organisme : King Abdullah University of Science and Technology
ID : BAS/1/1020-01-01
Pays : International
Organisme : FWO (Odysseus)
ID : G0F8316N
Pays : International
Références
Lancet Respir Med. 2014 Apr;2(4):321-38
pubmed: 24717628
Virus Evol. 2018 Jan 08;4(1):vex042
pubmed: 29340210
Emerg Infect Dis. 2013 Mar;19(3):449-55
pubmed: 23622714
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
J Clin Microbiol. 2014 Jul;52(7):2615-24
pubmed: 24829250
Bioinformatics. 2012 Nov 15;28(22):2991-3
pubmed: 23014632
Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4865-70
pubmed: 15024109
Curr Opin Microbiol. 1999 Oct;2(5):489-93
pubmed: 10508723
Antimicrob Agents Chemother. 2011 Jun;55(6):2515-22
pubmed: 21444711
Infect Immun. 2003 Dec;71(12):6962-70
pubmed: 14638785
PLoS Pathog. 2019 Sep 12;15(9):e1008067
pubmed: 31513651
J Clin Microbiol. 2012 Mar;50(3):995-1002
pubmed: 22170931
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Microbes Infect. 2010 Jun;12(6):467-75
pubmed: 20215000
Lancet Infect Dis. 2018 Apr;18(4):431-440
pubmed: 29326013
Sci Rep. 2017 Aug 23;7(1):9227
pubmed: 28835627
J Bacteriol. 2006 Jan;188(2):759-72
pubmed: 16385065
S Afr Med J. 1972 Mar 25;46(13):354-8
pubmed: 5074542
PLoS One. 2014 Jul 10;9(7):e102135
pubmed: 25010492
Bioinformatics. 2008 Dec 1;24(23):2672-6
pubmed: 18845581
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Nat Commun. 2014 Sep 01;5:4812
pubmed: 25176035
J Bacteriol. 1998 Jul;180(14):3541-7
pubmed: 9657995
J Antimicrob Chemother. 2017 Mar 1;72(3):684-690
pubmed: 28031270
Emerg Infect Dis. 2002 Aug;8(8):843-9
pubmed: 12141971
Emerg Infect Dis. 2013 Jun;19(6):969-76
pubmed: 23735084
PLoS Med. 2015 Sep 29;12(9):e1001880
pubmed: 26418737
Int J Tuberc Lung Dis. 2011 Mar;15(3):344-51
pubmed: 21333101
Br Med J. 1961 Mar 4;1(5226):636-8
pubmed: 13693888
Antimicrob Agents Chemother. 2004 Jul;48(7):2415-23
pubmed: 15215089
Tuberculosis (Edinb). 2011 Jan;91(1):1-7
pubmed: 20980199
Antimicrob Agents Chemother. 2008 Oct;52(10):3805-9
pubmed: 18694954
Nat Genet. 2015 Mar;47(3):242-9
pubmed: 25599400
J Clin Microbiol. 1994 Jun;32(6):1542-6
pubmed: 7915723
Clin Infect Dis. 2019 Sep 13;69(7):1229-1231
pubmed: 30933266
PLoS One. 2012;7(10):e46688
pubmed: 23056405
Elife. 2018 Oct 30;7:
pubmed: 30373719
Lancet Respir Med. 2017 Apr;5(4):269-281
pubmed: 28109869
Euro Surveill. 2007 May 17;12(5):E070517.1
pubmed: 17868596
J Clin Microbiol. 2006 Jan;44(1):254-6
pubmed: 16390984
Infect Genet Evol. 2012 Jun;12(4):637-41
pubmed: 21723420
Nat Genet. 2018 Feb;50(2):307-316
pubmed: 29358649
S Afr Med J. 1959 Mar 28;33(13):265-7
pubmed: 13646880
Lancet Respir Med. 2019 Mar;7(3):249-259
pubmed: 30630778
J Clin Microbiol. 2013 Jun;51(6):1818-25
pubmed: 23554196
Mol Biol Evol. 2015 Jan;32(1):268-74
pubmed: 25371430
Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9677-82
pubmed: 10944230
Science. 2006 Jun 30;312(5782):1944-6
pubmed: 16809538
J Clin Microbiol. 2007 May;45(5):1483-90
pubmed: 17360841
J Clin Microbiol. 2009 Jun;47(6):1773-80
pubmed: 19339475
PLoS Med. 2013;10(2):e1001387
pubmed: 23424287
J Clin Microbiol. 2005 Jul;43(7):3185-91
pubmed: 16000433
Gene. 1992 Mar 1;112(1):117-22
pubmed: 1551589
Nucleic Acids Res. 2012 Jan;40(2):e12
pubmed: 22102585
Antimicrob Agents Chemother. 2013 Feb;57(2):827-32
pubmed: 23208709
Tuberculosis (Edinb). 2014 Dec;94(6):649-56
pubmed: 25459163
Infect Genet Evol. 2008 May;8(3):323-30
pubmed: 18378194
Chest. 2009 Aug;136(2):420-425
pubmed: 19349380
BMC Genomics. 2015 Oct 24;16:857
pubmed: 26496891
Nat Methods. 2017 Jun;14(6):587-589
pubmed: 28481363
Genome Med. 2015 May 27;7(1):51
pubmed: 26019726
Clin Infect Dis. 2012 Feb 15;54(4):579-81
pubmed: 22190562